| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention can be used for the investigation of TRAIL-mediated apoptosis mechanisms, and as a therapeutic agent for treating DR5-dependent tumours. The mutations Y189N/R191K/Q193R/H264R/I266L/D267Q/D269H or Y189N/R191K7 Q193R/H264R/I266L/D269H are introduced in human TRAIL found in plasmid DNA pET32a that is followed with the transformation of Escherichia coli BL21 (DE3) strain of the produced recombinant plasmid DNA, expression and recovery of target protein. ^ EFFECT: invention allows producing recombinant mutant human TRAIL with high antineoplastic activity. ^ 3 dwg, 3 tbl, 5 ex |
